Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis

Infliximab, an inhibitor of TNF-α, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline serum TNF-α could be considered as a key indicator for optimal dosing of infliximab for RA treatment to achieve the clinical response and its sus...

Descripción completa

Detalles Bibliográficos
Autores principales: Oba, Koji, Horie, Nao, Sato, Norihiro, Saito, Kazuyoshi, Takeuchi, Tsutomu, Mimori, Tsuneyo, Miyasaka, Nobuyuki, Koike, Takao, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898537/
https://www.ncbi.nlm.nih.gov/pubmed/29696196
http://dx.doi.org/10.1016/j.conctc.2017.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898537/
https://www.ncbi.nlm.nih.gov/pubmed/29696196
http://dx.doi.org/10.1016/j.conctc.2017.08.007

Ejemplares similares